Fulgent Genetics Q1 revenue falls

Fulgent Genetics

01/05/2026 12:08

Overview

Genetic testing and therapeutics firm's Q1 revenue fell yr/yr to $71.1 mln

Company repurchased 2.6 mln shares for $40.1 mln in Q1

Fulgent reiterated full-year 2026 revenue guidance

Outlook

Fulgent Genetics expects 2026 revenue of approximately $350.0 mln

Company anticipates 2026 non-GAAP loss of about $46.0 mln, or $(1.59) per share

Fulgent expects gross margins to normalize and improve in the second half of 2026

Result Drivers

LABORATORY SERVICES - Co said laboratory services segment delivered solid results in Q1

THERAPEUTIC PIPELINE - Co highlighted advances in clinical candidates FID-007 and FID-022

Company press release: ID:nBw5qxxy3a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$71.14 mln
$68.10 mln (2 Analysts)
Q1 Adjusted EBITDA
Miss
-$15.20 mln
-$9.98 mln (2 Analysts)
Q1 Gross Profit
$21.49 mln
Q1 Operating Expenses
$56.11 mln
Q1 Operating Income
-$34.62 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Fulgent Genetics Inc is $26.00, about 71.2% above its April 30 closing price of $15.19

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)